20.500.12556/DiRROS-20455 Cannabinoids and triple-negative breast cancer treatment Triple-negative breast cancer (TNBC) accounts for about 10-20% of all breast cancer cases and is associated with an unfavorable prognosis. Until recently, treatment options for TNBC were limited to chemotherapy. A new successful systemic treatment is immunotherapy with immune checkpoint inhibitors, but new tumor-specific biomarkers are needed to improve patient outcomes. Cannabinoids show antitumor activity in most preclinical studies in TNBC models and do not appear to have adverse effects on chemotherapy. Clinical data are needed to evaluate efficacy and safety in humans. Importantly, the endocannabinoid system is linked to the immune system and immunosuppression. Therefore, cannabinoid receptors could be a potential biomarker for immune checkpoint inhibitor therapy or a novel mechanism to reverse resistance to immunotherapy. In this article, we provide an overview of the currently available information on how cannabinoids may influence standard therapy in TNBC. triple-negative breast cancer breast cancer cancer treatment cannabinoids trojno negativni rak dojke rak dojke onkološko zdravljenje kanabinoidi true false true Frontiers Media SA Basel, Switzerland Angleški jezik Slovenski jezik by Authors Neznano 2024-09-18 14:44:06 2024-09-18 14:44:07 2024-09-19 03:34:36 0000-00-00 00:00:00 2024 0 Basel 0 Nasl. z nasl. zaslona; Opis vira z dne 9. 8. 2024; str. 1-13 Vol. 15 Aug. 2024 0000-00-00 Zaloznikova Objavljeno apc 2024-02-15 2024-07-15 2024-08-08 618.1 1664-3224 10.3389/fimmu.2024.1386548 204044547 https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1386548/full 1 f15b9326-75aa-11ef-9d3a-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=28820 RAZ_Dobovisek_Luka_2024.pdf RAZ_Dobovisek_Luka_2024.pdf 1 94085E57E4C165B8D20A7131A0D384EB 238f068613a879167d9d4849ec2b6cfb0e1b0a07bb43eadb501d5fcf3e212b20 6450a9a4-75ab-11ef-9d3a-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=28821 Onkološki inštitut Ljubljana 0 0 0